Presentation

Company Profile
IRLAB is a drug development company focused on developing treatments of Parkinson’s disease (PD) and other life-altering diseases that affect the central nervous system (CNS). The two clinical candidates, Mesdopetam (Phase IIb/III) and Pirepemat (Phase IIb), aim to treat the most troublesome symptoms related to PD: involuntary movements occurring upon long-term use of levodopa (i.e. LIDs) and impaired balance leading to falls, respectively. IRLAB’s drug candidates are based on its proprietary research platform, ISP (The Integrative Screening Process). In addition to the clinical candidates, the ISP platform has generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq First North Premier Growth Market.

Recent highlights
In March 2021, IRLAB announced that the first European patients had been dosed in the Phase IIb/III Mesdopetam study. In May, the company announced that Mesdopetam’s Phase I results had been published in the journal “Pharmacology Research & Perspectives”. In June, the company announced that Pirepemat’s Phase I results had been published in the journal “Clinical Pharmacology in Drug Development”. IN July, IRLAB announced that it entered a licensing agreement with the global biopharmaceutical company Ipsen. The agreement involves exclusive worldwide development and commercial rights to Mesdopetam.

Outlook
The company’s focus lies on the ongoing Phase IIb/III study with Mesdopetam as well as the preparations of the Phase IIb study with Pirepemat. Top-line results from the Mesdopetam study are expected H1 2021.